New Content  edit
Get The App!

Loading the player...
SIRT versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB Study)
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Dr. Pierce Chow discusses SIRT versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB Study) at ASCO 2017. For the ability to view on your mobile phone please visit us at

This transcript is software driven, please understand there may be errors.  Should any inaccuracies or omissions be found, please notify for correction.

Hi. I'm Professor Pierce Chow, Surgical Oncologist at the National Cancer Center, Singapore and the DukeNUS Medical school. I'm going to present to you the results of a pivotal clinical trial in liver cancer that was presented earlier at ASCO 2017. This important clinical trial looks at patients with, what we call, locally advanced liver cancer and we are comparing two therapies. One of them is selective internal radiation therapy, which is a brachytherapy therapy introduced through the artery. And the other one is sorafenib, which is an oral molecular targeted therapy that the patient takes as a continuous dose.

So in this clinical trial, what we have shown is that, while there is no difference in the overall survival between these two treatments in these patients, one of the treatments, selective internal radiation, or SIRT, significantly reduces the tumor size much more than the other one. It was 23.1 verus 1.7 percent. More importantly, the group of patients treated on the SIRT suffered significantly fewer side effects than the patients on the sorafenib. This holds true through all AEs and also for patients with treatment-related AEs.

So, in summary, what the trial shows is that the use of SIRT is now a viable alternative for patients with locally advanced liver cancer and this is very important for them because adverse event profile is much better with this therapy. Thank you.